BR112012030794A2 - novos compostos imunoadjuvantes e usos dos mesmos - Google Patents

novos compostos imunoadjuvantes e usos dos mesmos

Info

Publication number
BR112012030794A2
BR112012030794A2 BR112012030794A BR112012030794A BR112012030794A2 BR 112012030794 A2 BR112012030794 A2 BR 112012030794A2 BR 112012030794 A BR112012030794 A BR 112012030794A BR 112012030794 A BR112012030794 A BR 112012030794A BR 112012030794 A2 BR112012030794 A2 BR 112012030794A2
Authority
BR
Brazil
Prior art keywords
new
compounds
immunoadjuvant
immunoadjuvant compounds
new immunoadjuvant
Prior art date
Application number
BR112012030794A
Other languages
English (en)
Other versions
BR112012030794B1 (pt
Inventor
Martirosyan Anna
Klechevsky Aynav
Banchereau Jacques
Gorvel Jean-Pierre
Oh Sangkon
Original Assignee
Centre Nat Rech Scient
Inserm ( Inst Nat De La Santé Et De La Rech Médicale)
Univ D'aix-Marseille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Inserm ( Inst Nat De La Santé Et De La Rech Médicale), Univ D'aix-Marseille filed Critical Centre Nat Rech Scient
Publication of BR112012030794A2 publication Critical patent/BR112012030794A2/pt
Publication of BR112012030794B1 publication Critical patent/BR112012030794B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

novos compostos imunoadjuvantes e uso dos mesmos. a presente invenção se refere a um composto de beta glucano cíclico para uso como um imunoadjuvante e composição de vacina que compreende o mesmo. estes novos compostos adjuvantes representam, em particular, uma nova classe de moléculas de ativação de células dendríticas.
BR112012030794-0A 2010-06-04 2011-06-06 Novos compostos imunoadjuvantes e usos dos mesmos BR112012030794B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10305596 2010-06-04
EP10305596.8 2010-06-04
PCT/EP2011/059287 WO2011151471A1 (en) 2010-06-04 2011-06-06 Novel immunoadjuvant compounds and uses thereof

Publications (2)

Publication Number Publication Date
BR112012030794A2 true BR112012030794A2 (pt) 2017-05-23
BR112012030794B1 BR112012030794B1 (pt) 2019-11-26

Family

ID=42790846

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012030794-0A BR112012030794B1 (pt) 2010-06-04 2011-06-06 Novos compostos imunoadjuvantes e usos dos mesmos

Country Status (9)

Country Link
US (1) US9061066B2 (pt)
EP (1) EP2575877B1 (pt)
JP (1) JP5860871B2 (pt)
KR (1) KR101736487B1 (pt)
CN (1) CN103096923B (pt)
BR (1) BR112012030794B1 (pt)
CA (1) CA2800424C (pt)
ES (1) ES2607798T3 (pt)
WO (1) WO2011151471A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064855A1 (en) * 2011-09-12 2013-03-14 Baylor Research Institute Reprogramming immune environment in breast cancer via dendritic cells
CN102600462B (zh) * 2012-03-29 2015-06-17 戚春建 人树突状细胞肿瘤疫苗及其制备方法和应用
CN102600467B (zh) * 2012-03-29 2016-06-01 戚春建 β-葡聚糖在制备人树突状细胞肿瘤疫苗中的应用
EP3703737A4 (en) 2017-10-30 2021-08-18 University of Southern California COMPOSITIONS AND METHODS FOR A SINGLE MULTI-ADJUVANT APPROACH IN IMMUNOPROPHYLAXIS TO PREVENT INFECTIONS
US20210187064A1 (en) * 2018-05-07 2021-06-24 Administrators Of The Tulane Educational Fund Mutated e. coli enterotoxins as anti-inflammatory agents
AU2020221280A1 (en) * 2019-02-15 2021-09-09 Cleveland Clinic Foundation Vaccine adjuvants and formulations
WO2023183080A1 (en) 2022-03-21 2023-09-28 University Of Southern California Triple vaccine protects against bacterial and fungal pathogens via trained immunity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4532009A (en) 1983-04-01 1985-07-30 Albany International Forming board elements
JPS6170994A (ja) 1984-09-14 1986-04-11 Daikin Ind Ltd 環状（１→２）−β−Ｄ−グルカンの製法
US6444210B1 (en) * 1996-07-03 2002-09-03 Her Majesty the Queen in right of Canada, as represented by the Minister of National Defence of Her Majesty′s Canadian Goverment Bacterial and synthetic polysaccharide immunomodulators that enhance general immunity
US6303347B1 (en) * 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
ATE320847T1 (de) 2000-08-18 2006-04-15 Massachusetts Inst Technology Vorrichtung und verfahren zur automatisierten synthese von oligosacchariden
JP2006517914A (ja) 2002-09-20 2006-08-03 デンドレオン コーポレイション 中ないし高分化型がんの免疫療法用組成物および治療方法。
EP1550458A1 (en) * 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1787660A1 (en) * 2005-11-22 2007-05-23 GBF Gesellschaft für Biotechnologische Forschung mbH New adjuvants on the basis of bisacyloxypropylcysteine conjugates and their uses in pharmaceutical compositions
SI2865387T1 (sl) * 2008-11-21 2019-10-30 Kobenhavns Univ University Of Copenhagen Primiranje imunskega odziva

Also Published As

Publication number Publication date
CA2800424A1 (en) 2011-12-08
KR20130130674A (ko) 2013-12-02
JP5860871B2 (ja) 2016-02-16
BR112012030794B1 (pt) 2019-11-26
EP2575877B1 (en) 2016-10-19
US9061066B2 (en) 2015-06-23
EP2575877A1 (en) 2013-04-10
KR101736487B1 (ko) 2017-05-17
US20130129756A1 (en) 2013-05-23
CN103096923A (zh) 2013-05-08
CN103096923B (zh) 2017-11-14
CA2800424C (en) 2018-10-23
WO2011151471A1 (en) 2011-12-08
ES2607798T3 (es) 2017-04-04
JP2013527219A (ja) 2013-06-27

Similar Documents

Publication Publication Date Title
BR112012030794A2 (pt) novos compostos imunoadjuvantes e usos dos mesmos
BR112015014753B8 (pt) composições, uso de uma composição, método para o combate de fungos fitopatogênicos e uso dos componentes
BR112015015031A2 (pt) processo de glicoconjugação
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
BR112012007257A2 (pt) Uso de pelo menos um composto, processo de conservação de uma composição, composto e composições cosmética e dermatológica
EA201791744A2 (ru) Улучшенная липидная композиция
BR112014007134A2 (pt) usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto
UY31942A (es) Formulaciones de adyuvante comprendiendo combinaciones de triterpenoides, esteroles, inmunomoduladores, polímeros y estimuladores de th2, procedimientos de preparación, composiciones y aplicaciones.
BR112015005168A2 (pt) Derivados de c17-alcanodiila e alquenodiila de ácido oleanólico e métodos de uso dos mesmos
TR201908003T4 (tr) TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
BR112012004698A2 (pt) métodos de redução de atividade virucida em composições de pcv-2 e composições de pcv-2 com uma imonugenicidade aprimorada.
BR112012020628A2 (pt) fotoiniciador de éter polialquílico, uso de um fotoiniciador de éter polialquílico, método para curar uma composição de matriz, e, composição de matriz
BR112014013085A2 (pt) forma cristalina do ticagrelor, processo para a preparação da forma cristalina do ticagrelor, composição farmacêutica e processo para preparar uma composição farmacêutica
BR112015007843A2 (pt) método para a preparação de um polímero, polímero, artigo e método de preparação de um artigo
BR112013001109A2 (pt) composição que contém galacto-oligossacarídeos e método para produzi-la
ECSP14004595A (es) 2-tiopirimidinonas
BRPI0916069C1 (pt) composto, usos de um composto, composição farmacêutica, composição cosmética e usos cosméticos de uma composição
BR112015002464B8 (pt) processo para a preparação de carbamat-benzoxazinona, carbamat-benzoxazinona e uso da carbamat-benzoxazinona
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
BR112013014388A2 (pt) suspensão aquosa de um inibidor de encefalinase e processo de preparação de uma suspensão aquosa
BR112012017393A2 (pt) derivados de 2,5,7-oxazolpirimidina substituída
BR112014027047A2 (pt) nova formulação
BR112012009310A2 (pt) composto, e, composição farmacêutica

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: INSERM ( INSTITUT NATIONAL DE LA SANTE ET DE LA RE

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/06/2011, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/06/2011, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2778 DE 02-04-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.